Tech companies gain favor of Congress in bid to relax regulations

Laura Pedulli | | Health Exec | Digital Transformation

A lobbying campaign by technology companies that will profit from selling digital health has been successful so far, reports Politico.

In the past few weeks, the FDA has promised not to regulate technologies that receive, transmit, store or display data from medical devices, while indicating that it will not regulate most low-risk mobile apps, according to the story.

Read more below:

Despite FDA moves, push continues for Congress to act on mobile health

Laura Pedulli

Related Content

From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI
Healthcare-specific AI: How to multiply successes and head off accidents

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.